Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02702180
Registration number
NCT02702180
Ethics application status
Date submitted
28/02/2016
Date registered
8/03/2016
Date last updated
12/04/2023
Titles & IDs
Public title
Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis
Query!
Scientific title
A Randomised, Double-blind, Placebo-controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Patients
Query!
Secondary ID [1]
0
0
2015-003878-33
Query!
Secondary ID [2]
0
0
MOL-PAP-002
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
IMPALA
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Autoimmune Pulmonary Alveolar Proteinosis
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Autoimmune diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Molgramostim
Treatment: Drugs - Placebo
Treatment: Devices - PARI eFlow nebulizer system
Experimental: Double-blind molgramostim once daily - Inhalation of molgramostim nebuliser solution 300 mcg once daily for 24 weeks
Experimental: Double-blind molgramostim intermittent - Inhalation of molgramostim nebuliser solution 300 mcg for 7 days and placebo nebuliser solution for 7 days for 24 weeks (12 cycles)
Placebo Comparator: Double-blind placebo - Inhalation of placebo nebuliser solution once daily for 24 weeks
Experimental: Open-label molgramostim intermittent - Inhalation of molgramostim nebuliser solution 300 mcg for 7 days and placebo nebuliser solution for 7 days for 24 or 48 weeks from completion of the double-blind period
Treatment: Drugs: Molgramostim
300 mcg molgramostim (rhGM-CSF) nebulizer solution for inhalation
Treatment: Drugs: Placebo
Placebo nebulizer solution for inhalation
Treatment: Devices: PARI eFlow nebulizer system
PARI eFlow nebulizer system
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Treatment: Devices
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Absolute Change From Baseline of Alveolar-arterial Oxygen Concentration (A-a(DO2)) After 24 Weeks of Treatment
Query!
Assessment method [1]
0
0
Measurement of (A-a)DO2 was done by blood gas analysis. An arterial blood sample was collected in the supine position, after resting for at least 10 minutes (or longer if required to achieve stable oxygen saturation). The sample was analyzed for arterial oxygen tension (PaO2) and partial pressure of carbon dioxide (PaCO2). The calculation of (A-a)DO2 was done centrally by using a formula described in the protocol.
Query!
Timepoint [1]
0
0
From baseline to 24 weeks
Query!
Secondary outcome [1]
0
0
Change From Baseline in 6-minute Walking Distance (6MWD) After 24 Weeks of Treatment
Query!
Assessment method [1]
0
0
The 6MWD was assessed by the use of 6-minute walking test (6MWT). The 6MWT was performed in accordance with the 2014 ATS/ERS guideline "field walking tests in chronic respiratory disease" (Holland et al. 2014) by technicians with documented training and experience.
Where possible, the test was conducted with the participant breathing ambient atmospheric air. If the participant required oxygen supplementation at rest, a titration procedure was carried out as part of the 6MWT at screening in order to determine the oxygen flow rate required for the participant to complete the test. This flow rate was to be used during subsequent tests, if possible.
Query!
Timepoint [1]
0
0
From baseline to 24 weeks
Query!
Secondary outcome [2]
0
0
Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score After 24 Weeks of Treatment
Query!
Assessment method [2]
0
0
The SGRQ is designed to measure health impairment in patients with asthma and chronic obstructive pulmonary disease (COPD). It consists of two parts, where Part 1 covers the participants' recollection of their symptoms over the preceding period (1 month recall used in this trial, Symptoms component) and Part 2 addresses the participants' current state in terms of disturbances to their daily physical activity (Activity component) and a wide range of disturbances of psycho-social function (Impact component). A total score as well as individual component scores were calculated. Scores (total and component) range from 0 to 100, with higher scores indicating more limitations.
Query!
Timepoint [2]
0
0
From baseline to 24 weeks
Query!
Secondary outcome [3]
0
0
Number of Whole Lung Lavage During 24 Weeks of Treatment
Query!
Assessment method [3]
0
0
In all versions of the protocol (no participants were recruited under version 1.0), whole lung lavage (single lung or both lungs) was applied as rescue therapy. In protocol version 2.0, the criterion for performing whole lung lavage was an increase in (A-a)DO2 by more than 10 mmHg/1.33 kilopascal compared to baseline. In protocol version 3.0 onwards, the criterion for performing whole lung lavage was clinical worsening of aPAP based on symptoms, reduced exercise capacity and/or findings of hypoxemia or desaturation according to the investigator's judgement.
In protocol versions 2.0 and 3.0, participants undergoing whole lung lavage during the double-blind period were to discontinue double-blind treatment, encouraged to continue to follow the same visit schedule and, if required, receive further whole lung lavage at the investigator's discretion. In protocol version 4.0 and 5.0, participants undergoing whole lung lavage were to continue double-blind treatment.
Query!
Timepoint [3]
0
0
From baseline to 24 weeks
Query!
Secondary outcome [4]
0
0
Number of Adverse Events (AEs) During 24 Weeks of Treatment
Query!
Assessment method [4]
0
0
Treatment-emergent adverse events (AEs) were assessed on or after the first dose of trial drug to 28 days after last dose.
Information about AEs was collected by the investigator by a non-leading question such as "have you experienced any new health problems or worsening of existing conditions" and by reporting events directly observed or spontaneously volunteered by participants (e.g., in the Subject Diary Card, where subjects were asked to record any AEs and answer questions regarding lung toxicity and known systemic effects). Participants were also encouraged to contact the clinic in between visits if they experienced AEs or had any concerns.
All AEs were assessed by the investigator for severity (mild, moderate, severe), outcome (recovered, not recovered, recovered with sequelae, fatal, unknown) and causality (unlikely, possible, probable, not applicable) according to current regulatory standards.
Query!
Timepoint [4]
0
0
From baseline to 24 weeks
Query!
Secondary outcome [5]
0
0
Number of Serious Adverse Events (SAEs) During 24 Weeks of Treatment
Query!
Assessment method [5]
0
0
SAEs are defined as any untoward medicinal occurrence or effect that at any dose:
Results in death
Is life-threatening
Requires hospitalisation or prolongation of existing hospitalisation
Results in persistent or significant disability or incapacity
Is a congenital anomaly or birth defect
May jeopardise the subject or may require intervention to prevent one or more of the other outcomes listed above (Important Medical Events)
Query!
Timepoint [5]
0
0
From baseline to 24 weeks
Query!
Secondary outcome [6]
0
0
Number of Adverse Drug Reactions (ADRs) During 24 Weeks of Treatment
Query!
Assessment method [6]
0
0
All AEs judged by either the reporting investigator or the sponsor as having a reasonable causal relationship to a medicinal product qualify as ADRs. The expression reasonable causal relationship means that a causal relationship between a medicinal product and an AE is at least a reasonable possibility i.e. the relationship cannot be ruled out.
Query!
Timepoint [6]
0
0
From baseline to 24 weeks
Query!
Secondary outcome [7]
0
0
Number of Severe AEs During 24 Weeks of Treatment
Query!
Assessment method [7]
0
0
All AEs were assessed by the investigator for severity (mild, moderate, severe) according to current regulatory standards:
Mild: The AE is easily tolerated and does not interfere with daily activity.
Moderate: The AE interferes with daily activity, but the subject is still able to function. Medical intervention may be considered.
Severe: The AE is incapacitating and requires medical intervention.
Query!
Timepoint [7]
0
0
From baseline to 24 weeks
Query!
Secondary outcome [8]
0
0
Number of Participants With at Least 1 AE Leading to Treatment Discontinuation During 24 Weeks of Treatment
Query!
Assessment method [8]
0
0
Participants could be discontinued from treatment and assessments at any time, if deemed necessary by the investigator. Potential reasons for discontinuation of treatment included e.g. unacceptable AE.
Query!
Timepoint [8]
0
0
From baseline to 24 weeks
Query!
Eligibility
Key inclusion criteria
- aPAP diagnosed by computed tomography, or by biopsy, or by Broncho Alveolar Lavage
(BAL), and by increased GM-CSF autoantibodies in serum.
- Stable or progressive aPAP during a minimum period of 2 months prior to the Baseline
visit.
- Arterial oxygen tension (PaO2) <75 mmHg/<10 kilo Pascal (kPa) at rest, OR desaturation
of >4 percentage points on the 6MWT
- An alveolar-arterial oxygen difference [(A-a)DO2] of minimum 25 mmHg/3.33 kPa
- Female or male =18 years of age
- Females who have been post-menopausal for >1 year or females of childbearing potential
after a confirmed menstrual period using a highly efficient method of contraception
(i.e. a method with <1% failure rate such as combined hormonal contraception,
progesterone-only hormonal contraception, intrauterine device, intrauterine
hormone-releasing system, bilateral tubal occlusion, vasectomised partner, sexual
abstinence), during and until 30 days after last dose of double-blind trial treatment.
Females of childbearing potential must have a negative serum pregnancy test at
Screening (Visit 1) and a negative urine pregnancy test at dosing at Baseline (Visit
2) and must not be lactating
- Males agreeing to use condoms during and until 30 days after last dose of double-blind
medication, or males having a female partner who is using adequate contraception as
described above
- Willing and able to provide signed informed consent
- Willing and able to comply with scheduled visits, treatment plan, laboratory tests,
and other trial procedures specified in the protocol as judged by the investigator
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Diagnosis of hereditary or secondary PAP
- WLL within 1 month of Baseline
- Treatment with GM-CSF within 3 months of Baseline
- Treatment with rituximab within 6 months of Baseline
- Treatment with plasmapheresis within 3 months of Baseline
- Treatment with any investigational medicinal product within 4 weeks of Screening
- Concomitant use of sputum modifying drugs such as carbocysteine or ambroxol
- History of allergic reactions to GM-CSF
- Connective tissue disease, inflammatory bowel disease or other autoimmune disorder
requiring treatment associated with significant immunosuppression, e.g. more than 10
mg/day systemic prednisolone
- Previous experience of severe and unexplained side-effects during aerosol delivery of
any kind of medicinal product
- History of, or present, myeloproliferative disease or leukaemia
- Known active infection (viral, bacterial, fungal or mycobacterial)
- Apparent pre-existing concurrent pulmonary fibrosis
- Any other serious medical condition which in the opinion of the investigator would
make the participant unsuitable for the trial
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
21/03/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
27/09/2019
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
139
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
0
0
Royal Prince Alfred Hospital - Sydney
Query!
Recruitment postcode(s) [1]
0
0
2050 - Sydney
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Ohio
Query!
Country [4]
0
0
Denmark
Query!
State/province [4]
0
0
Aarhus
Query!
Country [5]
0
0
France
Query!
State/province [5]
0
0
Rennes
Query!
Country [6]
0
0
Germany
Query!
State/province [6]
0
0
Essen
Query!
Country [7]
0
0
Germany
Query!
State/province [7]
0
0
Gauting
Query!
Country [8]
0
0
Germany
Query!
State/province [8]
0
0
Heidelberg
Query!
Country [9]
0
0
Germany
Query!
State/province [9]
0
0
Lübeck
Query!
Country [10]
0
0
Greece
Query!
State/province [10]
0
0
Athens
Query!
Country [11]
0
0
Israel
Query!
State/province [11]
0
0
Peta? Tiqwa
Query!
Country [12]
0
0
Italy
Query!
State/province [12]
0
0
Pavia
Query!
Country [13]
0
0
Japan
Query!
State/province [13]
0
0
Niigata
Query!
Country [14]
0
0
Japan
Query!
State/province [14]
0
0
Osaka
Query!
Country [15]
0
0
Japan
Query!
State/province [15]
0
0
Sendai
Query!
Country [16]
0
0
Japan
Query!
State/province [16]
0
0
Toyohashi
Query!
Country [17]
0
0
Japan
Query!
State/province [17]
0
0
Yokohama
Query!
Country [18]
0
0
Korea, Republic of
Query!
State/province [18]
0
0
Seoul
Query!
Country [19]
0
0
Netherlands
Query!
State/province [19]
0
0
Nieuwegein
Query!
Country [20]
0
0
Portugal
Query!
State/province [20]
0
0
Lisboa
Query!
Country [21]
0
0
Portugal
Query!
State/province [21]
0
0
Porto
Query!
Country [22]
0
0
Russian Federation
Query!
State/province [22]
0
0
St. Petersburg
Query!
Country [23]
0
0
Slovakia
Query!
State/province [23]
0
0
Vyšné Hágy
Query!
Country [24]
0
0
Spain
Query!
State/province [24]
0
0
Barcelona
Query!
Country [25]
0
0
Switzerland
Query!
State/province [25]
0
0
Lausanne
Query!
Country [26]
0
0
Turkey
Query!
State/province [26]
0
0
Istanbul
Query!
Country [27]
0
0
United Kingdom
Query!
State/province [27]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Savara Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study evaluates inhaled molgramostim (recombinant human granulocyte macrophage-colony
stimulating factor [rhGM-CSF]) in the treatment of autoimmune pulmonary alveolar proteinosis
(aPAP) patients. A third of the patients will receive inhaled molgramostim once daily for 24
weeks, a third will receive inhaled molgramostim intermittently (7 days on, 7 days off) for
24 weeks and a third will receive inhaled matching placebo for 24 weeks.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02702180
Query!
Trial related presentations / publications
Trapnell BC, Inoue Y, Bonella F, Morgan C, Jouneau S, Bendstrup E, Campo I, Papiris SA, Yamaguchi E, Cetinkaya E, Ilkovich MM, Kramer MR, Veltkamp M, Kreuter M, Baba T, Ganslandt C, Tarnow I, Waterer G, Jouhikainen T; IMPALA Trial Investigators. Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis. N Engl J Med. 2020 Oct 22;383(17):1635-1644. doi: 10.1056/NEJMoa1913590. Epub 2020 Sep 7.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Cliff Morgan, MD
Query!
Address
0
0
Royal Brompton Hospital London
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02702180
Download to PDF